![Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology](https://www.jimmunol.org/content/jimmunol/181/1/146/F7.large.jpg)
Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology
![Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology](https://www.jimmunol.org/content/jimmunol/181/1/146/F5.large.jpg)
Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties | The Journal of Immunology
![Percentage (range) of ER-Positive Cells and Mean Fluorescence Channel... | Download Scientific Diagram Percentage (range) of ER-Positive Cells and Mean Fluorescence Channel... | Download Scientific Diagram](https://www.researchgate.net/profile/Awtar-Krishan/publication/341386971/figure/tbl1/AS:891221723598848@1589495225341/Percentage-range-of-ER-Positive-Cells-and-Mean-Fluorescence-Channel-MFC-Ratio-of-25.png)
Percentage (range) of ER-Positive Cells and Mean Fluorescence Channel... | Download Scientific Diagram
![Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram](https://www.researchgate.net/profile/Panteleimon-Kountourakis/publication/43132163/figure/fig2/AS:330189788729344@1455734788034/Patients-with-pathological-response-have-longer-TTR-48-months-17-84-than-patients.png)
Patients with pathological response have longer TTR [48 months (17–84)]... | Download Scientific Diagram
![PDF) Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties PDF) Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties](https://i1.rgstatic.net/publication/5288968_Identification_of_a_Novel_Immunogenic_HLA-A0201-Binding_Epitope_of_HER-2neu_with_Potent_Antitumor_Properties/links/00b49521da0610a280000000/largepreview.png)
PDF) Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties
![CD4 + CD161 + cells stimulated via CD3/CD28 suppress autologous PBMC... | Download Scientific Diagram CD4 + CD161 + cells stimulated via CD3/CD28 suppress autologous PBMC... | Download Scientific Diagram](https://i1.rgstatic.net/publication/6652930_Increased_Frequency_of_CD4_Cells_Expressing_CD161_in_Cancer_Patients/links/563238fc08ae242468d986cb/largepreview.png)
CD4 + CD161 + cells stimulated via CD3/CD28 suppress autologous PBMC... | Download Scientific Diagram
![The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression](https://www.spandidos-publications.com/ISSUE_IMAGES/ijo_42_5.jpg)
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
Frequency of positivity (a) and median values (b) for ER c (circles)... | Download Scientific Diagram
![The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression](https://www.spandidos-publications.com/article_images/ijo/42/5/IJO-42-05-1770-g00.jpg)
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression
![PDF) Properties with Potent Antitumor neu HER2/ HLA-A*0201Binding Epitope of Identification of a Novel Immunogenic PDF) Properties with Potent Antitumor neu HER2/ HLA-A*0201Binding Epitope of Identification of a Novel Immunogenic](https://i1.rgstatic.net/publication/237495612_Properties_with_Potent_Antitumor_neu_HER2_HLA-A0201Binding_Epitope_of_Identification_of_a_Novel_Immunogenic/links/004635285d2be3b79f000000/largepreview.png)
PDF) Properties with Potent Antitumor neu HER2/ HLA-A*0201Binding Epitope of Identification of a Novel Immunogenic
![PDF) Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: A multimodality approach for locally advanced breast cancer PDF) Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: A multimodality approach for locally advanced breast cancer](https://i1.rgstatic.net/publication/43132163_Neoadjuvant_sequential_epirubicin_and_docetaxel_followed_by_surgery-radiotherapy_and_post-operative_docetaxel_or_gemcitabinevinorelbine_combination_based_on_primary_response_A_multimodality_approach_f/links/56c4c00008ae7fd4625a451b/largepreview.png)
PDF) Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: A multimodality approach for locally advanced breast cancer
![Relative quantification of the CEACAM19 expression via real-time PCR.... | Download Scientific Diagram Relative quantification of the CEACAM19 expression via real-time PCR.... | Download Scientific Diagram](https://www.researchgate.net/profile/Kleita-Michaelidou/publication/236077368/figure/fig2/AS:616378423836679@1523967476229/Relative-quantification-of-the-CEACAM19-expression-via-real-time-PCR-A-A.png)